Cargando…
Post-bone marrow transplant patient management.
Increasingly, bone marrow transplant (BMT) is the treatment of choice for certain hematologic diseases. BMT is, however, a risky procedure with many potentially serious complications. Some complications are the result of the conditioning regimen, a stage of transplantation that includes large doses...
Autor principal: | |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Yale Journal of Biology and Medicine
1990
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2589364/ https://www.ncbi.nlm.nih.gov/pubmed/2293508 |
_version_ | 1782161103900377088 |
---|---|
author | Poliquin, C. M. |
author_facet | Poliquin, C. M. |
author_sort | Poliquin, C. M. |
collection | PubMed |
description | Increasingly, bone marrow transplant (BMT) is the treatment of choice for certain hematologic diseases. BMT is, however, a risky procedure with many potentially serious complications. Some complications are the result of the conditioning regimen, a stage of transplantation that includes large doses of chemotherapy and/or radiation therapy. Conditioning-induced neutropenia and thrombocytopenia often result in infection, bleeding, and mucositis. Veno-occlusive disease (VOD), a chemotherapy-induced hepatotoxicity, can cause a mild to severe form of liver disease. Other complications are directly attributable to the engrafted new marrow. Graft-versus-host disease, a rejection process initiated by immunocompetent donor T lymphocytes, is a complication frequently observed in allogeneic BMT. Approximately 14-28 days after the day of transplant, signs of engraftment begin to appear. When specific discharge criteria are met, the BMT patient is discharged from the hospital. Specific follow-up medical care is ongoing for about one year after BMT. |
format | Text |
id | pubmed-2589364 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1990 |
publisher | Yale Journal of Biology and Medicine |
record_format | MEDLINE/PubMed |
spelling | pubmed-25893642008-11-28 Post-bone marrow transplant patient management. Poliquin, C. M. Yale J Biol Med Research Article Increasingly, bone marrow transplant (BMT) is the treatment of choice for certain hematologic diseases. BMT is, however, a risky procedure with many potentially serious complications. Some complications are the result of the conditioning regimen, a stage of transplantation that includes large doses of chemotherapy and/or radiation therapy. Conditioning-induced neutropenia and thrombocytopenia often result in infection, bleeding, and mucositis. Veno-occlusive disease (VOD), a chemotherapy-induced hepatotoxicity, can cause a mild to severe form of liver disease. Other complications are directly attributable to the engrafted new marrow. Graft-versus-host disease, a rejection process initiated by immunocompetent donor T lymphocytes, is a complication frequently observed in allogeneic BMT. Approximately 14-28 days after the day of transplant, signs of engraftment begin to appear. When specific discharge criteria are met, the BMT patient is discharged from the hospital. Specific follow-up medical care is ongoing for about one year after BMT. Yale Journal of Biology and Medicine 1990 /pmc/articles/PMC2589364/ /pubmed/2293508 Text en |
spellingShingle | Research Article Poliquin, C. M. Post-bone marrow transplant patient management. |
title | Post-bone marrow transplant patient management. |
title_full | Post-bone marrow transplant patient management. |
title_fullStr | Post-bone marrow transplant patient management. |
title_full_unstemmed | Post-bone marrow transplant patient management. |
title_short | Post-bone marrow transplant patient management. |
title_sort | post-bone marrow transplant patient management. |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2589364/ https://www.ncbi.nlm.nih.gov/pubmed/2293508 |
work_keys_str_mv | AT poliquincm postbonemarrowtransplantpatientmanagement |